Alteraciones de la función hepática en los pacientes infectados por covid-19 remitidos a UCI en el año 2020 a través del SCORE MELD en una institución prestadora de servicios en salud de Barranquilla (At, Co)
| datacite.rights | http://purl.org/coar/access_right/c_16ec | |
| dc.contributor.advisor | Cadena Bonfanti, Andres Angélo | |
| dc.contributor.advisor | González Torres, Henry Joseth | |
| dc.contributor.author | Tirado Romero, Gloria Ibis | |
| dc.contributor.author | Moran Marín, Leinad Yamile | |
| dc.date.accessioned | 2021-12-02T17:30:31Z | |
| dc.date.available | 2021-12-02T17:30:31Z | |
| dc.date.issued | 2021 | |
| dc.description.abstract | La infección por SARS COV2/ COVID 2019, es una enfermedad cuya sintomatología común es fiebre, tos, dolor de garganta, cefalea, disnea, mialgias, náuseas, vómitos, diarreas, dolor abdominal y pérdida del apetito. Se ha observado, que a pesar del gran compromiso pulmonar, las alteraciones hepáticas, también se deben considerar, asociandose a las formas más graves y a mayor mortalidad. OBJETIVO: Caracterizar las alteraciones en la bioquímica hepática en una cohorte de pacientes con Covid-19 del año 2020 en una Institución Prestadora de Servicios en Salud de Barranquilla (At, Co). METODOLOGÍA: Se realizò un diseño retrospectivo, longitudinal, con profundidad analítica y un carácter de medida cuantitativo, en 754 pacientes mayores de edad ingresados a una unidad de cuidados intensivos con prueba RT-PCR positiva durante el año 2020. Se creó una base de datos provenientes de las historias clínicas de estos. RESULTADOS: Al evaluar pacientes con COVID-19, con el MELD Score, el valor promedio global fue de 7.07±7.62 y con una mediana 5.49. Para los sobrevivientes el valor promedio de 5.37±7.52 y una mediana de 4.29, mientras que de los fallecidos fue de 9.45±7.22 con una mediana de 8.02 [RIC 4.35 – 14.24], estos resultados indican la asociación entre un Score alto para MELD y un desenlace fatal. CONCLUSION: En este estudio se observò que los marcadores inflamatorios en los pacientes con Covid-19 con bioquímica hepática anormal, evaluados a través de la escala Model for End-Stage Liver Disease constituyen un elemento de importancia para predecir la respuesta de los pacientes infectados con Covid-19. | spa |
| dc.description.abstract | SARS COV2 / COVID 2019 infection is a disease whose common symptoms are fever, cough, sore throat, headache, dyspnea, myalgia, nausea, vomiting, diarrhea, abdominal pain and loss of appetite. It has been observed that despite the great pulmonary involvement, liver alterations should also be considered, associated with the most severe forms and with higher mortality. OBJECTIVE: To characterize the alterations in liver biochemistry in a cohort of patients with Covid-19 from 2020 in a Health Service Provider Institution of Barranquilla (At, Co). METHODOLOGY: A retrospective, longitudinal design was carried out, with analytical depth and a quantitative measurement character, in 754 patients of legal age admitted to an intensive care unit with a positive RT-PCR test during 2020. A database was created from their medical records. RESULTS: When evaluating patients with COVID-19, with the MELD Score, the global mean value was 7.07 ± 7.62 and with a median 5.49. For the survivors, the mean value of 5.37 ± 7.52 and a median of 4.29, while for the deceased it was 9.45 ± 7.22 with a median of 8.02 [IQR 4.35 - 14.24], these results indicate the association between a high Score for MELD and a fatal outcome. CONCLUSION: In this study it was observed that inflammatory markers in patients with Covid-19 with abnormal liver biochemistry, evaluated through the Model for End-Stage Liver Disease scale, constitute an important element to predict the response of patients infected with Covid-19. | eng |
| dc.format.mimetype | ||
| dc.identifier.uri | https://hdl.handle.net/20.500.12442/9186 | |
| dc.language.iso | spa | |
| dc.publisher | Ediciones Universidad Simón Bolivar | spa |
| dc.publisher | Facultad de Ciencias de la Salud | spa |
| dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | eng |
| dc.rights.accessrights | info:eu-repo/semantics/restrictedAccess | eng |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | |
| dc.subject | COVID-19 | spa |
| dc.subject | MELD Score | spa |
| dc.subject | Alteraciones en la bioquímica hepática | spa |
| dc.subject | Unidad de cuidados intensivos | spa |
| dc.subject | COVID-19 | eng |
| dc.subject | MELD Score | eng |
| dc.subject | Alterations in liver biochemistry | eng |
| dc.subject | Intensive care unit | eng |
| dc.title | Alteraciones de la función hepática en los pacientes infectados por covid-19 remitidos a UCI en el año 2020 a través del SCORE MELD en una institución prestadora de servicios en salud de Barranquilla (At, Co) | spa |
| dc.type.driver | info:eu-repo/semantics/other | |
| dc.type.spa | Otros | |
| dcterms.references | Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb;395(10223):497–506 doi.org/10.1016/S0140-6736(20)30183-5. | eng |
| dcterms.references | Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020 Apr;382(18):1708–20 DOI: 10.1056 / NEJMoa2002032 | eng |
| dcterms.references | Luo S, Zhang X, Xu H. Don’t Overlook Digestive Symptoms in Patients With 2019 Novel Coronavirus Disease (COVID-19). Clin Gastroenterol Hepatol. 2020 Jun;18(7):1636–7. https://doi.org/10.1016/j.cgh.2020.03.043. | eng |
| dcterms.references | Plasencia-martínez JM, Rovira À, Domínguez PC, Barber I, García-garrigós E, Arenas-jiménez JJ. Manifestaciones extratorácicas de la COVID-19 en nos adultos y presentación de la enfermedad en ni ˜. Radiologia. 2021;63(4):370–83. https://dx.doi.org/10.1016/2Fj.rx.2020.11.003 | spa |
| dcterms.references | Cardinale V, Capurso G, Ianiro G, Gasbarrini A, Arcidiacono PG, Alvaro D. Intestinal permeability changes with bacterial translocation as key events modulating systemic host immune response to SARS-CoV-2: A working hypothesis. Dig Liver Dis. 2020 Dec;52(12):1383–9. https://dx.doi.org/10.1016/2Fj.dld.2020.09.009 | eng |
| dcterms.references | Bhayana R, Som A, Li MD, Carey DE, Anderson MA, Blake MA, et al. Abdominal Imaging Findings in COVID-19: Preliminary Observations. Radiology. 2020 Oct;297(1):E207–15. https://doi.org/10.1148/radiol.2020201908 | eng |
| dcterms.references | Goldberg-Stein S, Fink A, Paroder V, Kobi M, Yee J, Chernyak V. Abdominopelvic CT findings in patients with novel coronavirus disease 2019 (COVID-19). Abdom Radiol. 2020 Sep;45(9):2613–23. doi. 10.1007 / s00261-020-02669-2. | eng |
| dcterms.references | Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020 Feb;395(10223):507–13. doi: 10.1016 / S0140-6736 (20) 30211-7. | eng |
| dcterms.references | Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA - J Am Med Assoc. 2020 Mar;323(11): Doi: 10.1001 / jama.2020.1585 | eng |
| dcterms.references | Pan L, Mu M, Yang P, Sun Y, Wang R, Yan J, et al. Clinical Characteristics of COVID-19 Patients With Digestive Symptoms in Hubei, China: A Descriptive, Cross-Sectional, Multicenter Study. Am J Gastroenterol. 2020 May;115(5):766–73. doi: 10.14309 / ajg.0000000000000620. | eng |
| dcterms.references | Xu L, Liu J, Lu M, Yang D, Zheng X. Liver injury during highly pathogenic human coronavirus infections. Liver Int. 2020 May;40(5):998–1004. doi: 10.1111 / liv.14435 | eng |
| dcterms.references | Cai Q, Huang D, Ou P, Yu H, Zhu Z, Xia Z, et al. COVID‐19 in a designated infectious diseases hospital outside Hubei Province, China. Allergy. 2020 Jul;75(7):1742–52. doi: 10.1111 / all.14309 | eng |
| dcterms.references | Huang Y, Yang R, Xu Y, Gong P. Clinical characteristics of 36 non-survivors with COVID-19 in Wuhan, China. 2020; doi.org/10.1101/2020.02.27.20029009 | eng |
| dcterms.references | Zhang B, Zhou X, Qiu Y, Song Y, Feng F, Feng J, et al. Clinical characteristics of 82 cases of death from COVID-19. Jin X, editor. PLoS One. 2020 Jul;15(7):e0235458. doi.org/10.1371/journal.pone.0235458 | eng |
| dcterms.references | Yousif WI. Reply to: “Characteristics and in-hospital outcomes of COVID-19 patients with acute or subacute liver failure.” Dig Liver Dis. 2021 Jun;(xxxx):32–3. | eng |
| dcterms.references | Wang Y, Liu S, Liu H, Li W, Lin F, Jiang L, et al. SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19. J Hepatol. 2020 Oct;73(4):807–16. doi: 10.1016 / j.jhep.2020.05.002 | eng |
| dcterms.references | Manterola C, Sol M, Ottone N, Otzen T. Anatomía Quirúrgica y Radiológica del Hígado. Fundamentos para las Resecciones Hepáticas. Int J Morphol. 2017;35(4):1525–40 available from https%3A%2F%2Fscielo.conicyt.cl%2Fpdf%2Fijmorphol%2Fv35n4%2F0717-9502-ijmorp | spa |
| dcterms.references | Lee S, Divens L, Fowler LH. The Role of Liver Function in the Setting of Cirrhosis with Chronic Infection and Critical Illness. Crit Care Nurs Clin North Am. 2017 Mar;29(1):37–50. doi: 10.1016 / j.cnc.2016.09.006. | eng |
| dcterms.references | Potrillé L, Prawl M, Ramos O, Fernandez R. Cambios morfofuncionales del hígado en la cirrosis hepática. Gac Med Estud. 2020;53(9):1689–99. | spa |
| dcterms.references | Rojas M, Milán R, Delgado A, Bizarro P, Cano G, Cafaggi D, et al. El hepatocito como un ejemplo de interacción entre la biología celular y las rutas metabólicas. Rev Fac Med UNAM. 2017;60(2):52–8.available from chromeextension://efaidnbmnnnibpcajpcglclefindmkaj/viewer.html?pdfurl=https%3A%2F%2Fwww.medigraphic.com%2Fpdfs%2Ffacmed%2Fun-2017%2Fun172j.pdf&clen=324824&chunk=true | spa |
| dcterms.references | Vayne C, Gruel Y, Pouplard C. Hemostasia: fisiología y principales pruebas de exploración. EMC - Tratado Med. 2021 Mar;25(1):1–10. Doi: 10.1016/S1636-5410(21)44685-4 | spa |
| dcterms.references | Orts P. LOS RETINOIDES, EL ETANOL Y EL HÍGADO. Vol. 2019. universitas Miguel Hernandez; 2019. //efaidnbmnnnibpcajpcglclefindmkaj/viewer.html?pdfurl=http%3A%2F%2F193.147.134.18%2Fbitstream%2F11000%2F6909%2F1%2FOrts%2520Le%25C3%25B3n%252C%2520Paula.pdf&clen=1469867 | spa |
| dcterms.references | Younossi ZM, Stepanova M, Afendy M, Fang Y, Younossi Y, Mir H, et al. Changes in the Prevalence of the Most Common Causes of Chronic Liver Diseases in the United States From 1988 to 2008. Clin Gastroenterol Hepatol. 2011 Jun;9(6):524-530.e1. DOI: 10.1016 / j.cgh.2011.03.020. | eng |
| dcterms.references | Lampertico P, Agarwal K, Berg T, Buti M, Janssen HLA, Papatheodoridis G, et al. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017 Aug;67(2):370–98. DOI: 10.1016 / j.jhep.2017.03.021 | eng |
| dcterms.references | Carrasco NM, Ortega AM, Santamaría DB, Villajos LT. Alteración de las pruebas de función hepática en el paciente inmunodeprimido. Med - Programa Form Médica Contin Acreditado. 2020 Mar;13(5):282–6. Available from https://dialnet.unirioja.es/servlet/articulo?codigo=7296808 | spa |
| dcterms.references | Rodríguez M, Buti M, Esteban R, Lens S, Prieto M, Suárez E, et al. Documento de consenso de la Asociación Española para el Estudio del Hígado sobre el tratamiento de la infección por el virus de la hepatitis B (2020). Gastroenterol Hepatol. 2020 Nov;43(9):559–87. DOI: 10.1016/j.gastrohep.2020.03.011 | spa |
| dcterms.references | Mok CC. Hepatitis B and C infection in patients undergoing biologic and targeted therapies for rheumatic diseases. Best Pract Res Clin Rheumatol. 2018 Dec;32(6):767–80. DOI: 10.1016 / j.berh.2019.03.008 | eng |
| dcterms.references | Dienstag JL, Ghany MG, Morgan TR, Di Bisceglie AM, Bonkovsky HL, Kim H-Y, et al. A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. Hepatology. 2011 Aug;54(2):396–405. DOI: 10.1002 / hep.24370 | eng |
| dcterms.references | Pawlotsky J-M, Negro F, Aghemo A, Berenguer M, Dalgard O, Dusheiko G, et al. EASL recommendations on treatment of hepatitis C: Final update of the series☆. J Hepatol. 2020 Nov;73(5):1170–218. DOI: 10.1016 / j.jhep.2020.08.018 | eng |
| dcterms.references | Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016 Jul;64(1):73–84. DOI: 10.1002 / hep.28431 | eng |
| dcterms.references | Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011 Aug;34(3):274–85. DOI: 10.1111 / j.1365-2036.2011.04724.x | eng |
| dcterms.references | Bruguera M. Envejecimiento y enfermedades del hígado. Gastroenterol Hepatol. 2014 Nov;37(9):535–43. DOI: 10.1016/j.gastrohep.2014.04.005 | spa |
| dcterms.references | Yki-Järvinen H. Nutritional modulation of nonalcoholic fatty liver disease and insulin resistance: human data. Curr Opin Clin Nutr Metab Care. 2010 Nov;13(6):709–14. DOI: 10.1097 / MCO.0b013e32833f4b34 | eng |
| dcterms.references | Aller R, Fernández-Rodríguez C, lo Iacono O, Bañares R, Abad J, Carrión JA, et al. Documento de consenso. Manejo de la enfermedad hepática grasa no alcohólica (EHGNA). Guía de práctica clínica. Gastroenterol Hepatol. 2018 May;41(5):328–49. doi.org/10.1016/j.gastrohep.2017.12.003 | spa |
| dcterms.references | Wong RJ, Aguilar M, Cheung R, Perumpail RB, Harrison SA, Younossi ZM, et al. Nonalcoholic Steatohepatitis Is the Second Leading Etiology of Liver Disease Among Adults Awaiting Liver Transplantation in the United States. Gastroenterology. 2015 Mar;148(3):547–55. DOI: 10.1053 / j.gastro.2014.11.039 | eng |
| dcterms.references | Bataller R, Cabezas J, Aller R, Ventura-Cots M, Abad J, Albillos A, et al. Enfermedad hepática por alcohol. Guías de práctica clínica. Documento de consenso auspiciado por la AEEH. Gastroenterol Hepatol. 2019 Dec;42(10):657–76. //doi.org/10.1016/j.gastrohep.2019.09.006 | spa |
| dcterms.references | Lazarte R, Pavez C, Poniachik J. Enfermedad hepática por alcohol. Av en Hepatol. 2016;27:142–62.available from chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/viewer.html?pdfurl=https%3A%2F%2Fgastrolat.org%2FDOI%2FPDF%2F10.0716%2Fgastrolat2016n100003.pdf&clen=1326979&chunk=true | spa |
| dcterms.references | Gao B, Bataller R. Alcoholic Liver Disease: Pathogenesis and New Therapeutic Targets. Gastroenterology. 2011 Nov;141(5):1572–85. DOI: 10.1053 / j.gastro.2011.09.002 | eng |
| dcterms.references | Scaglione S, Kliethermes S, Cao G, Shoham D, Durazo R, Luke A, et al. The Epidemiology of Cirrhosis in the United States. J Clin Gastroenterol. 2015 Sep;49(8):690–6. DOI: 10.1097 / MCG.0000000000000208 | eng |
| dcterms.references | Simpson RF, Hermon C, Liu B, Green J, Reeves GK, Beral V, et al. Alcohol drinking patterns and liver cirrhosis risk: analysis of the prospective UK Million Women Study. Lancet Public Heal. 2019 Jan;4(1):e41–8. DOI: 10.1016 / S2468-2667 (18) 30230-5 | eng |
| dcterms.references | Roesch-Dietlen F, González-Santes M, Sánchez-Maza YJ, Díaz-Roesch F, Cano-Contreras AD, Amieva-Balmori M, et al. Influencia de los factores socioeconómicos y culturales en la etiología de la cirrosis hepática. Rev Gastroenterol México. 2021 Jan;86(1):28–35. DOI: 10.1016/j.rgmx.2020.01.00 | spa |
| dcterms.references | Aceves-Martins M. Cuidado nutricional de pacientes con cirrosis hepática. Nutr Hosp. Available from:2014;29(2):246–58. https://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S0212-16112014000200003 | spa |
| dcterms.references | García Buey L, González Mateos F, Moreno-Otero R. Cirrosis hepática. Med - Programa Form Médica Contin Acreditado. 2012 Jan;11(11):625–33. Available from https://dialnet.unirioja.es/servlet/articulo?codigo=3927342 | spa |
| dcterms.references | Björnsson ES, Bergmann OM, Björnsson HK, Kvaran RB, Olafsson S. Incidence, Presentation, and Outcomes in Patients With Drug-Induced Liver Injury in the General Population of Iceland. Gastroenterology. 2013 Jun;144(7):1419-1425.e3. DOI: 10.1053 / j.gastro.2013.02.006 | eng |
| dcterms.references | Reig M, Forner A, Ávila MA, Ayuso C, Mínguez B, Varela M, et al. Diagnóstico y tratamiento del carcinoma hepatocelular. Actualización del documento de consenso de la AEEH, AEC, SEOM, SERAM, SERVEI y SETH. Med Clin (Barc). 2021 Jan;(xx). /doi.org/10.1016/j.medcli.2020.09.022 | spa |
| dcterms.references | Omata M, Cheng A-L, Kokudo N, Kudo M, Lee JM, Jia J, et al. Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017 Jul;11(4):317–70. DOI: 10.1007 / s12072-017-9799-9 | eng |
| dcterms.references | Kwo PY, Cohen SM, Lim JK. ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries. Am J Gastroenterol. 2017 Jan;112(1):18–35. DOI: 10.1038 / ajg.2016.517 | eng |
| dcterms.references | Mathias VP, Baena MS, Pérez RG, Torres JAC. ¿Cómo valorar la etiología de una alteración aguda de la función hepática? FMC - Form Médica Contin en Atención Primaria. 2020 Aug;27(7):329–36. Available from https://dialnet.unirioja.es/servlet/articulo?codigo=7561973 | spa |
| dcterms.references | Arrese J. M, Barrera M. F. Virtudes y defectos del índice MELD. Gastroenterol latinoam. 2010;21(Tabla 3):515–8. Available from chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/viewer.html?pdfurl=https%3A%2F%2Fgastrolat.org%2FDOI%2F | spa |
| dcterms.references | Sanhueza E, Contreras J, Zapata R, Sanhueza M, Elgueta F, López C, et al. Evaluación comparativa entre MELD y Child-Pugh como escalas pronósticas de sobrevida en pacientes con cirrosis hepática en Chile. Rev Med Chil. 2017 Jan;145(1):17–24. Doi.org/10.4067/s0034-9887201700010003 | spa |
| dcterms.references | Bernardi M, Gitto S, Biselli M. The MELD score in patients awaiting liver transplant: Strengths and weaknesses. J Hepatol. 2011 Jun;54(6):1297–306. | eng |
| dcterms.references | Available from: https://pubmed.ncbi.nlm.nih.gov/21145851/ | spa |
| dcterms.references | Aguirre J, Torre A, Vilatobá M, Contreras AG, Sánchez A, Antolinez J, et al. Indicaciones de trasplante hepático. es i Rev Investig Clínica. 2014;66:534–46. Available from: https://www.medigraphic.com/pdfs/revinvcli/nn-2014/nn146i.pdf | spa |
| dcterms.references | Gomez G, Melo S. VALIDEZ DE LA ESCALA PRONÓSTICA DE MELD EN El PACIENTE CON CiRROSIS HEPÁTICA HOSPITALIZADO EN El SERVICIO DE MEDICINA INTERNA DEL HOSPITAL NACIONAL RAMIRO PRIALÉ PRIALÉ - HUANCAYO AÑO 2011-2015". Universidad Nacional Del Centro Del Centro De Posgrado. Universidad Nacional Del Centro Del Peru; 2016. Available from: https://repositorio.uncp.edu.pe/ | spa |
| dcterms.references | Rodríguez A. Comparar la Escala de Child Pugh con el Modelo de Enfermedades Hepaticas Terminales como valor predictor de mortalidad en pacientes adultos Hospitalizados con diagnostico de cirrosis hepática descompensada. Escala Model for End-Stage Liver Disease (MELD); 2013. Available from: http://www.scielo.org.pe/scielo.php?script=sci_arttext&pid=S1022-51292015000400003 | spa |
| dcterms.references | Tian H, Liu Y, Li Y, Wu C-H, Chen B, Kraemer MUG, et al. An investigation of transmission control measures during the first 50 days of the COVID-19 epidemic in China. Science (80- ). 2020 May;368(6491):638–42. Available from: https://pubmed.ncbi.nlm.nih.gov/32234804/ | eng |
| dcterms.references | Sun K, Chen J, Viboud C. Early epidemiological analysis of the coronavirus disease 2019 outbreak based on crowdsourced data: a population-level observational study. Lancet Digit Heal. 2020 Apr;2(4):e201–8. Available from: https://www.thelancet.com/journals/landig/article/PIIS2589-7500%2820%2930026-1/fulltex | eng |
| dcterms.references | Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R. COVID-19 infection: Emergence, transmission, and characteristics of human coronaviruses. J Adv Res. 2020 Jul;24:91–8. Available from: https://pubmed.ncbi.nlm.nih.gov/31987001/ | spa |
| dcterms.references | Chan JF-W, Kok K-H, Zhu Z, Chu H, To KK-W, Yuan S, et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect. 2020 Jan;9(1):221–36. Available from: https://pubmed.ncbi.nlm.nih.gov/31987001/ | eng |
| dcterms.references | Correia G, Rodrigues L, Gameiro da Silva M, Gonçalves T. Airborne route and bad use of ventilation systems as non-negligible factors in SARS-CoV-2 transmission. Med Hypotheses. 2020 Aug;141(April):109781. Available from: https://pubmed.ncbi.nlm.nih.gov/32361528/ | eng |
| dcterms.references | Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia. N Engl J Med. 2020 Mar;382(13):1199–207. Available from: https://www.nejm.org/doi/full/10.1056/nejmoa2001316 | eng |
| dcterms.references | Velavan TP, Meyer CG. The COVID‐19 epidemic. Trop Med Int Heal. 2020 Mar;25(3):278–80. Available from: https://pubmed.ncbi.nlm.nih.gov/32052514/ | eng |
| dcterms.references | Yang Y, Peng F, Wang R, Guan K, Jiang T, Xu G, et al. The deadly coronaviruses: The 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China. J Autoimmun. 2020 May;109(March 2020):102434. Available from: https://pubmed.ncbi.nlm.nih.gov/32143990/ | eng |
| dcterms.references | Algwaiz G, Aljurf M, Koh M, Horowitz MM, Ljungman P, Weisdorf D, et al. Real-World Issues and Potential Solutions in Hematopoietic Cell Transplantation during the COVID-19 Pandemic: Perspectives from the Worldwide Network for Blood and Marrow Transplantation and Center for International Blood and Marrow Transplant Research He. Biol Blood Marrow Transplant. 2020 Dec;26(12):2181–9. Available from: https://pubmed.nc bi.nlm.nih.gov/32717432/ | eng |
| dcterms.references | Lampton LM. Covid-19. In: Terapia actual de Conn’s 2021. 2021. p. 554–8. https://www.elsevier.com/books/conns-current-therapy-2021/bresnahan/978-0-323- 79006-2 | spa |
| dcterms.references | Sun J, He W-T, Wang L, Lai A, Ji X, Zhai X, et al. COVID-19: Epidemiology, Evolution, and Cross-Disciplinary Perspectives. Trends Mol Med. 2020 May;26(5):483–95. Available from: https://pubmed.ncbi.nlm.nih.gov/32359479/ | eng |
| dcterms.references | Xu B, Kraemer MUG, Xu B, Gutierrez B, Mekaru S, Sewalk K, et al. Open access epidemiological data from the COVID-19 outbreak. Lancet Infect Dis. 2020 May;20(5):534. Available from: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30119-5/fulltext | eng |
| dcterms.references | Velarde-Ruiz Velasco JA, García-Jiménez ES, Remes-Troche JM. Manifestaciones hepáticas y repercusión en el paciente cirrótico de COVID-19. Rev Gastroenterol México. 2020 Jul;85(3):303–11. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7250745/ | spa |
| dcterms.references | Vinken M. COVID-19 and the liver: an adverse outcome pathway perspective. Toxicology. 2021 May;455(February):152765. Available from: https://pubmed.ncbi.nlm.nih.gov/33771662/ | eng |
| dcterms.references | Zhang C, Shi L, Wang F-S. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol. 2020 May;5(5):428–30. Available from: https://pubmed.ncbi.nlm.nih.gov/32145190/ | eng |
| dcterms.references | Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA. 2020 May;323(20):2052. Available from: https://jamanetwork.com/journals/jama/fullarticle/2765184 | eng |
| dcterms.references | Giannis D, Ziogas IA, Gianni P. Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past. J Clin Virol. 2020 Jun;127(April):104362. Available from: https://pubmed.ncbi.nlm.nih.gov/32305883/ | eng |
| dcterms.references | Almas T, Ehtesham M, Khedro T, Haadi A, Nabeel AR, Hussain S, et al. The many faces of coronavirus disease 2019: COVID-19 and the liver. Ann Med Surg. 2021 Apr;64(February):102224. Available from:https://pubmed.ncbi.nlm.nih.gov/33747505/ | eng |
| dcterms.references | Schmit G, Lelotte J, Vanhaebost J, Horsmans Y, Van Bockstal M, Baldin P. The Liver in COVID-19-Related Death: Protagonist or Innocent Bystander? Pathobiology. 2021;88(1):88–94. Available from: https://www.karger.com/Article/FullText/512008 | eng |
| dcterms.references | Kunutsor SK, Laukkanen JA. Markers of liver injury and clinical outcomes in COVID-19 patients: A systematic review and meta-analysis. J Infect. 2021 Jan;82(1):159–98. Available from:https://pubmed.ncbi.nlm.nih.gov/32474033/ | eng |
| dcterms.references | Cai Q, Huang D, Yu H, Zhu Z, Xia Z, Su Y, et al. COVID-19: Abnormal liver function tests. J Hepatol. 2020 Sep;73(3):566–74. Available from: https://pubmed.ncbi.nlm.nih.gov/32298767/ | eng |
| dcterms.references | Shao T, Tong Y, Lu S, Jeyarajan AJ, Su F, Dai J, et al. Gamma‐Glutamyltransferase Elevation Is Frequent in Patients With COVID‐19: A Clinical Epidemiologic Study. Hepatol Commun. 2020 Dec;4(12):1744–50. Available from: https://aasldpubs.onlinelibrary.wiley.com/doi/full/10.1002/hep4.1576 | eng |
| dcterms.references | Zou B, Yeo YH, Jeong D, Sheen E, Park H, Nguyen P, et al. Higher mortality and hospital charges in patients with cirrhosis and acute respiratory illness: a population-based study. Sci Rep. 2018 Dec;8(1):9969. Available from:https://pubmed.ncbi.nlm.nih.gov/29967363/ | eng |
| dcterms.references | Mantovani A, Beatrice G, Dalbeni A. Coronavirus disease 2019 and prevalence of chronic liver disease: A meta‐analysis. Liver Int. 2020 Jun;40(6):1316–20. Available from:https://pubmed.ncbi.nlm.nih.gov/32329563/ | eng |
| dcterms.references | Pirola CJ, Sookoian S. COVID-19 and ACE2 in the Liver and Gastrointestinal Tract: Putative Biological Explanations of Sexual Dimorphism. Gastroenterology. 2020 Oct;159(4):1620–1. Available from:https://pubmed.ncbi.nlm.nih.gov/32348773/ | eng |
| dcterms.references | Seidu S, Gillies C, Zaccardi F, Kunutsor SK, Hartmann‐Boyce J, Yates T, et al. The impact of obesity on severe disease and mortality in people with SARS‐CoV‐2: A systematic review and meta‐analysis. Endocrinol Diabetes Metab. 2021 Jan;4(1):1–10. Available from: https://pubmed.ncbi.nlm.nih.gov/32904932/ | eng |
| dcterms.references | CDC COVID-19 Response Team. Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease 2019 — United States, February 12–March 28, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(13):382–6. Available from:https://pubmed.ncbi.nlm.nih.gov/32240123/ | eng |
| dcterms.references | Metawea MI, Yousif WI, Moheb I. COVID 19 and liver: An A–Z literature review. Dig Liver Dis. 2021 Feb;53(2):146–52. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7494329/ | eng |
| dcterms.references | Gao F, Zheng KI, Wang X, Yan H, Sun Q, Pan K, et al. Metabolic associated fatty liver disease increases coronavirus disease 2019 disease severity in nondiabetic patients. J Gastroenterol Hepatol. 2021 Jan;36(1):204–7. Available from: https://pubmed.ncbi.nlm.nih.gov/32436622/ | eng |
| dcterms.references | Fierro NA. COVID-19 and the liver: What do we know after six months of the pandemic? Ann Hepatol. 2020 Nov;19(6):590–1. Available from: https://pubmed.ncbi.nlm.nih.gov/32956871/ | eng |
| dcterms.references | Jothimani D, Venugopal R, Abedin MF, Kaliamoorthy I, Rela M. COVID-19 and the liver. J Hepatol. 2020 Nov;73(5):1231–40. Available from: https://pubmed.ncbi.nlm.nih.gov/32553666/ | eng |
| dcterms.references | Kovalic AJ, Satapathy SK, Thuluvath PJ. Prevalence of chronic liver disease in patients with COVID-19 and their clinical outcomes: a systematic review and meta-analysis. Hepatol Int. 2020 Sep;14(5):612–20. Available from: https://pubmed.ncbi.nlm.nih.gov/32725453/ | eng |
| dcterms.references | Colmenero J, Rodríguez-Perálvarez M, Salcedo M, Arias-Milla A, Muñoz-Serrano A, Graus J, et al. Epidemiological pattern, incidence, and outcomes of COVID-19 in liver transplant patients. J Hepatol. 2021 Jan;74(1):148–55. Available from: https://pubmed.ncbi.nlm.nih.gov/32750442/ | eng |
| dcterms.references | Wu J, Song S, Cao H-C, Li L-J. Enfermedades hepáticas en COVID-19: etiología, tratamiento y pronóstico. 2020;9327(19). Available from: https://pubmed.ncbi.nlm.nih.gov/32476793/ | spa |
| dcterms.references | Lei F, Liu Y, Zhou F, Qin J, Zhang P, Zhu L, et al. Longitudinal Association Between Markers of Liver Injury and Mortality in COVID‐19 in China. Hepatology. 2020 Aug;72(2):389–98. Available from: https://pubmed.ncbi.nlm.nih.gov/32359177/ | eng |
| dcterms.references | Li S, Li J, Zhang Z, Tan L, Shao T, Li M, et al. COVID-19 induced liver function abnormality associates with age. Aging (Albany NY). 2020 Jul;12(14):13895–904. Available from:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7425469/ | eng |
| dcterms.references | Zou X, Fang M, Li S, Wu L, Gao B, Gao H, et al. Characteristics of Liver Function in Patients With SARS-CoV-2 and Chronic HBV Coinfection. Clin Gastroenterol Hepatol. 2021 Mar;19(3):597–603. Available from:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7294291/ | eng |
| dcterms.references | Torre GM-D La, Montelongo-Mercado EA, Noyola-Villalobos HF, García-Ruiz A, Hernández-Díaz S, Santiago-Torres M, et al. Epidemiology of hospitalized patients with COVID-19 in a tertiary care hospital. Gac Med Mex [Internet]. 2021;157(3):237–44. Available from: http://www.ncbi.nlm.nih.gov/pubmed/34667312 | eng |
| dcterms.references | Boietti BR, Mirofsky M, Valentini R, Peuchot VA, Cámera LA, Pollán JA, et al. [Descriptive analysis of 4776 patients admitted to medical clinic services for COVID-19. Results of the Argentine Multi-Center Registry - REMA-COVID-19]. Medicina (B Aires) [Internet]. 2021;81(5):703–14. Available from: http://www.ncbi.nlm.nih.gov/pubmed/34633942 | eng |
| dcterms.references | Kaye AD, Cornett EM, Brondeel KC, Lerner ZI, Knight HE, Erwin A, et al. Biology of COVID-19 and related viruses: Epidemiology, signs, symptoms, diagnosis, and treatment. Best Pract Res Clin Anaesthesiol [Internet]. 2021 Oct;35(3):269–92. Available from: http://www.ncbi.nlm.nih.gov/pubmed/34511219 | eng |
| dcterms.references | Li J, He X, Yuan Yuan, Zhang W, Li X, Zhang Y, et al. Meta-analysis investigating the relationship between clinical features, outcomes, and severity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia. Am J Infect Control [Internet]. 2021;49(1):82–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32540370 | eng |
| dcterms.references | Wander P, Epstein M, Bernstein D. COVID-19 Presenting as Acute Hepatitis. Am J Gastroenterol [Internet]. 2020;115(6):941–2. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32301760 | eng |
| dcterms.references | Testino G, DI Biagio A, Fagoonee S, Pellicano R. SARS-CoV-2, alcohol consumption and liver injury. Minerva Med [Internet]. 2021 Oct 21; Available from: http://www.ncbi.nlm.nih.gov/pubmed/34672164 | eng |
| dcterms.references | Revzin M V., Raza S, Srivastava NC, Warshawsky R, D’Agostino C, Malhotra A, et al. Multisystem Imaging Manifestations of COVID-19, Part 2: From Cardiac Complications to Pediatric Manifestations. RadioGraphics. 2020 Nov;40(7):1866–92. Available from: https://pubmed.ncbi.nlm.nih.gov/33136488/ | eng |
| dcterms.references | Bruno RR, Wernly B, Hornemann J, Flaatten H, FjØlner J, Artigas A, et al. Early evaluation of organ failure using MELD-XI in critically ill elderly COVID-19 patients. Küpper J-H, Krüger-Genge A, Jung F, editors. Clin Hemorheol Microcirc [Internet]. 2021 Oct 6;79(1):109–20. Available from: https://www.medra.org/servlet/aliasResolver?alias=iospress&doi=10.3233/CH-219202 | spa |
| dcterms.references | Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar;395(10229):1054–62. Available from: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30566-3/fulltext | eng |
| dcterms.references | Chen F, Chen W, Chen J, Xu D, Xie W, Wang X, et al. Clinical features and risk factors of COVID-19-associated liver injury and function: A retrospective analysis of 830 cases. Ann Hepatol. 2021 Mar;21:100267. Available from: https://pubmed.ncbi.nlm.nih.gov/33053426/ | eng |
| oaire.version | info:eu-repo/semantics/acceptedVersion | |
| sb.programa | Especialización en Medicina Interna | spa |
| sb.sede | Sede Barranquilla | spa |